“Immuno-Oncology Therapeutics” Featuring Dr. Michael Alonso
On this episode of the Immunology Podcast, Dr. Michael Alonso from Bolt Biotherapeutics talks about using myeloid cells to target tumors.
Dr. Michael Alonso is a Scientific Co-Founder and Vice President of Immunology & Pharmacology at Bolt Biotherapeutics, a biotechnology company developing immunotherapies that activate myeloid cells. He discusses targeting tumors by covering them in “eat me” signals, considerations for moving drugs into the clinic, and building teams in biotech.
We had such an inspiring conversation with Dr. Alonso about science, entrepreneurship, and embracing challenges head on!
Dr. Brenda Raud, host
Find more episodes at immunologypodcast.com or wherever you get your podcasts.
This Episode's Immunology Roundup:
- Trade-Offs in Cancer Mutations – Researchers developed a model of hotspot mutations that shows fundamental trade-offs between a tumor’s growth and its visibility to the immune system.
- Reversing the T Cell Immune System – To determine how T cell lineage fates are determined in the thymus, scientists generated ‘FlipFlop’ mice with a functionally reversed T cell immune system.
- Gut Microbiota and Response to Viral Infection – Suppression of gut microbiota renders mice susceptible to systemic viral infections.
- Europe Cancer Immunotherapy Meeting Highlights – Scientists discussed antigenic dominance in lung cancer, next-generation CAR T cell design, and combining CAR T cell therapy with vaccination for solid tumors.
Request Pricing
Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
